Biomarin Pharmaceutical (BMRN) Short term Debt (2010 - 2024)

Biomarin Pharmaceutical has disclosed Short term Debt across 15 years of filings, most recently posting $494.8 million for Q2 2024.

• Quarterly Short term Debt changed N/A year-over-year to $494.8 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $494.8 million (changed N/A YoY) and the FY2023 annual result came in at $493.9 million, changed N/A from the prior year.
• Short term Debt was little changed at $494.8 million in Q2 2024, from $494.4 million in the prior quarter.
• Over five years, Short term Debt peaked at $494.8 million in Q2 2024 and troughed at $28.3 million in Q3 2022.
• A 5-year average of $221.2 million and a median of $64.0 million in 2022 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2020 — Short term Debt jumped 3642.9% — and 2021, when it plunged 91.58%.
• Tracing BMRN's Short term Debt over 5 years: stood at $374.3 million in 2020, then tumbled by 87.11% to $48.2 million in 2021, then tumbled by 41.32% to $28.3 million in 2022, then surged by 1644.96% to $493.9 million in 2023, then gained by 0.19% to $494.8 million in 2024.
• Business Quant data shows BMRN's Short term Debt at $494.8 million in Q2 2024, $494.4 million in Q1 2024, and $493.9 million in Q4 2023.